Withdrawals due to adverse events · Participants with Crohn's disease in remission
Adalimumab probably leads to lower withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Short‐term serious adverse events · people with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
Treatment related adverse events, · people with dry eye
1 finding from 1 review
Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF discontinuation showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF dose reduction showed no clear difference in withdrawals due to adverse events compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with sickle cell disease in a vaso‐occlusive crisis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults with sickle cell disease in a vaso‐occlusive crisis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events maximum · patients with suspected or diagnosed myocardial infarction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in withdrawals due to adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse events · newly diagnosed, transplant‐ineligible adults with symptomatic multiple myeloma
1 finding from 1 review
no estimate extracted
82 participants
GRADE not reported
Serious adverse events by 6 weeks · people with agitation in dementia
It is very uncertain whether valproate preparations changes serious adverse events by 6 weeks compared with placebo (very low certainty).
1 finding from 1 review
Adverse events at up to 2 months' · women with PMS
It is very uncertain whether acupuncture changes adverse events at up to 2 months' compared with sham (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
Elemental formula supplements showed no clear difference in withdrawals due to adverse events compared with polymeric formula supplements (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events/tolerance of feeds · patients undergoing surgery for head and neck cancer
It is very uncertain whether immunonutrition changes adverse events/tolerance of feeds compared with standard care (very low certainty).
1 finding from 1 review
Total adverse events at 12 months · septic arthritis in children taking antibiotics
1 finding from 1 review
Withdrawals due to adverse events · adults with chronic neuropathic pain
1 finding from 1 review
Serious adverse events: infection · people with implantable ventricular assist devices
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events: mortality · people with non‐cystic fibrosis bronchiectasis
1 finding from 1 review